Skip to content

On March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team. Learn more about this exciting combination at

Patient Safety & Product Quality

On the following Web pages, we invite you to learn more about the specific ways we ensure the safety and maintain the high standard of quality of Allergan’s products. You’ll learn about how patient safety fits within our research and development goals; how we assess the risk of our products and the importance of talking about risks and benefits of our products with your physician, and; the ways we go about ensuring the quality of our products throughout the manufacturing process.

Research and Development 
Talking About Risks and Benefits of Our Products 
Ensuring the Quality of Our Products